Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8943034

—

bf05806f-7ad1-5977-8b62-e97b9315bb8d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.470
  • IL6_JAK_STAT3_SIGNALING+0.430
  • INTERFERON_GAMMA_RESPONSE+0.430
  • ALLOGRAFT_REJECTION+0.420
  • INFLAMMATORY_RESPONSE+0.420
  • KRAS_SIGNALING_DN+0.420
  • PANCREAS_BETA_CELLS+0.400
  • COAGULATION+0.330
  • KRAS_SIGNALING_UP+0.290
  • MYOGENESIS+0.260

Top 10 suppressed

  • MYC_TARGETS_V1-0.630
  • MYC_TARGETS_V2-0.590
  • OXIDATIVE_PHOSPHORYLATION-0.550
  • UNFOLDED_PROTEIN_RESPONSE-0.510
  • TGF_BETA_SIGNALING-0.500
  • PROTEIN_SECRETION-0.490
  • DNA_REPAIR-0.430
  • MTORC1_SIGNALING-0.400
  • G2M_CHECKPOINT-0.380
  • MITOTIC_SPINDLE-0.380

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SRR1374115
brain-umap@2
GTEX—0.953
2SRR1331289
brain-umap@2
GTEX—0.950
3SRR598894
brain-umap@2
GTEX—0.948
4SRR607478
brain-umap@2
GTEX—0.945
5SRR1375203
brain-umap@2
GTEX—0.942
6TCGA-22-1005-01A-01R-0692-07
lung-landscapes@6
—cohortMD20.940
7SRR601006
brain-umap@2
GTEX—0.937
8SRR820379
brain-umap@2
GTEX—0.936
9SRR13311178
bladder-landscape@3
——0.934
10ERR2598336
medullo-epn-umap@date-based
fetalfetal0.931

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.470Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.430Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.430Idelalisib— uncovered
ALLOGRAFT_REJECTION0.420Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.420Idelalisib— uncovered
KRAS_SIGNALING_DN0.420Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.400Cobimetinib— uncovered
COAGULATION0.330Binimetinib— uncovered
KRAS_SIGNALING_UP0.290Inavolisib— uncovered
MYOGENESIS0.260Inavolisib— uncovered
ANGIOGENESIS0.240Remibrutinib— uncovered
COMPLEMENT0.240Inavolisib— uncovered
SPERMATOGENESIS0.210Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.200Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered
IL2_STAT5_SIGNALING0.190Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.170Inavolisib— uncovered
APICAL_SURFACE0.150Temsirolimus— uncovered
BILE_ACID_METABOLISM0.130Inavolisib— uncovered